Skip to main contentSkip to navigationSkip to search
Curasight

Press releases

2022

Transaction with shares in Curasight A/S made by managerial employee

September 4, 2022
 | Regulatory
COPENHAGEN – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS).  

The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted the 1 September 2022.

Curasight to present at HC Andersen Capital

August 25, 2022
 | Regulatory
Copenhagen, Denmark, 25 August 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q2 2022 at HC Andersen Capital, 29 August 2022.

Interim Report January – June 2022

August 25, 2022
 | Regulatory
Copenhagen, Denmark, 25 August 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby publishes the interim report for the period January 1 – June 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Recruitment completed in uPAR-PET study in brain cancer

June 30, 2022
 | Regulatory
Copenhagen, Denmark, 30 June 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that the investigator-initiated phase II study using uPAR-PET in brain cancer has now completed the inclusion of patients

Transaction with shares in Curasight A/S made by managerial employee

June 24, 2022
 | Regulatory
COPENHAGEN – Curasight A/S (“Curasight” or “the Company” - TICKER: CURAS).    

The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted in the period 9 – 10 June 2022.

Curasight issues warrants for launch of long-term incentive program

June 7, 2022
 | Regulatory
Copenhagen, Denmark, 7 June 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) announces today that it has issued a total of 956,770 warrants for the purpose of launching the Company’s long-term incentive program covering the Company’s Board of Directors, Executive Management and other key employees.

Interim Report January - March 2022

May 24, 2022
 | Regulatory
Curasight A/S (“Curasight” or “the Company” - TICKER: CURAS) hereby publishes the interim report for the period January 1 – March 31, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.

Curasight to present at Kapital Partners Life Science seminar

May 16, 2022
 | Regulatory
Curasight A/S (TICKER: CURAS) announced today that Chief Executive Officer Ulrich Krasilnikoff and Chief Scientific Officer professor Andreas Kjær will give an update on company strategy and progress in developing new treatment options for cancer diseases, at Kapital Partners Life Science seminar, 18 May 2022.

Resolutions of the Annual General Meeting of Curasight A/S

April 27, 2022
 | Regulatory
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held its Annual General Meeting on 27 April 2022 at 10:00 (CET) at the Company’s premises, Ole Maaløes Vej 3, room M7, DK-2200 Copenhagen N, Denmark.

Additional US patent application relating to uTRACE[®] is accepted for grant

April 22, 2022
 | Regulatory
The United States Patent and Trademark Office has announced that Curasight’s United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137. The patent strengthens Curasights IP protection and supports the US commercial strategy. 
Load more